Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$168.45
+$2.885 · +1.74%
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Regular session
$168.45
+$2.885 · +1.74%
Regular session · ET · Market data may be delayed.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Day range
Current $168.45
52-week range
Current $168.45
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
56
Fair Value
Sentiment
62
Bullish
Risk
48
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Day range
Current $168.45
52-week range
Current $168.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 982.02M USD | 739.02M USD | 563.95M USD | 449.54M USD | 373.65M USD |
| Cost of goods sold | 349.01M USD | 289.8M USD | 227.05M USD | 156.33M USD | 122.91M USD |
| Gross profit | 633.01M USD | 449.22M USD | 336.9M USD | 293.21M USD | 250.74M USD |
| Research and development | 364.19M USD | 347.75M USD | 367.19M USD | 373.81M USD | 263.22M USD |
| Selling, general, and administrative | 706.07M USD | 545.06M USD | 451.03M USD | 463.78M USD | 398.52M USD |
| Operating expenses | 1.07B USD | 892.81M USD | 901.62M USD | 837.59M USD | 661.74M USD |
| Interest income | 34.1M USD | 53.69M USD | 35.37M USD | 6.07M USD | 3.93M USD |
| Interest expense | 3.9M USD | 2.58M USD | 2.58M USD | 2.58M USD | 2.58M USD |
| Depreciation and amortization | 39.74M USD | 42.39M USD | 42.88M USD | 35.96M USD | 22.27M USD |
| Operating income | −437.25M USD | −443.59M USD | −564.73M USD | −544.38M USD | −411M USD |
| Net income | −416.28M USD | −436.37M USD | −479.45M USD | −654.59M USD | −405.67M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$201.4
19.56% upsidePrice history unavailable
High $225Average $201.4Low $180Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI636.52M0.03%2.3T USD0.03%$381.55+0.52%
Vanguard Morningstar Small-Cap ETFVB460.9M0.25%185.3B USD0.03%$288.74+0.38%
Vanguard Morningstar Small-Cap Growth ETFVBK264.54M0.58%44.7B USD0.05%$343.17+0.76%
Vanguard Extended Market ETFVXF244.98M0.25%95.4B USD0.05%$234.36+0.53%
iShares Russell Mid-Cap Growth ETFIWP106.7M0.54%19.88B USD0.23%$142.41+1.07%
ARK Genomic Revolution ETFARKG96.45M4.71%1.56B USD0.75%$51.38+4.24%
iShares Russell Mid-Cap ETFIWR88.83M0.16%55.97B USD0.18%$109.51+0.59%
iShares Russell 1000 Growth ETFIWF70.28M0.05%131.46B USD0.18%$127.85+0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell Mid-Cap Growth ETFIWPARK Genomic Revolution ETFARKGiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
